Gary Benson - Haematology Association of Ireland

More documents

Recommendations

Info

Eltrombopag and Median PlateletCounts:Median Platelet Count (x1,000/µL)RAISE• Phase III clinical trial• 26 weeks plus observationCheng G, et al. Blood. 2008;112:Abstract 400.
Eltrombopag Enhances Platelet Countand Ability to Initiate Interferon TherapyPatients With ≥ 100,000Platelets /µL at 4 WeeksPatients Entering Antiviral PhaseP ≤ 0.001 for each group vs PboMcHutchison J, et al. N Engl J Med. 2007;357:2227-2236.
Page 1 and 2: Overview of ITPDr Gary BensonDirect
Page 3: Statistics of ITP• Incidence of 2
Page 8 and 9: Aetiology of ITP : Children• Mate
Page 10 and 11: Diagnosis (of Exclusion)• Rule ou
Page 12 and 13: To Marrow or Not to Marrow?• Bone
Page 14 and 15: Management of ITP in Adults• Emer
Page 16 and 17: General Principles of Therapy• Ma
Page 18 and 19: When Planning Therapy…• Tailor
Page 20 and 21: Second-Line Therapy• IV Immune Gl
Page 22 and 23: Splenectomy• Usually reserved for
Page 24 and 25: Data from Fabris, F, et al. Br J Ha
Page 26 and 27: When all else fails…• Steroids
Page 28 and 29: Pathophysiology of ITPOAPOAutoantib
Page 30 and 31: Thrombopoietin Levels in ITP25025Pl
Page 32 and 33: Durable Responses in RomiplostimTri
Page 36 and 37: Emergency Treatment of Adult ITP•
Page 38 and 39: Treatment of Patients FailingPlatel

Gary Benson - Haematology Association of Ireland

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?